HB 6095 Summary

• Removes the Schedule V classification for FDA-approved drug products containing cannabidiol (CBD) derived from cannabis with no more than 0.1 percent residual tetrahydrocannabinols.

• Amends Florida Statutes section 893.03 to eliminate provisions that previously scheduled certain CBD-containing drug products as controlled substances.

• Updates the definition of "cannabis" in section 893.02 to exclude drug products meeting the FDA-approved CBD specifications described in section 893.03(5)(d).

• Takes effect upon becoming law.